Lauppe R, Nilsson FOL, Fues Wahl H, Lilja M, Vikström A, Asanin ST. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study. AO [Internet]. 2022 Nov. 2 [cited 2026 Jun. 18];61(11):1354-61. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/23842